The Antigen Presenting Potential of CD21(low) B Cells

Human CD21(low) B cells are expanded in autoimmune (AI) diseases and display a unique phenotype with high expression of co-stimulatory molecules, compatible with a potential role as antigen-presenting cells (APCs). Thus, we addressed the co-stimulatory capacity of naïve-like, IgM-memory, switched memory and CD27(neg)IgD(neg) memory CD21(low) B cells in allogenic co-cultures with CD4 T cells. CD21(low) B cells of patients with AI disorders expressed high levels of not only CD86, CD80, and HLA-DR (memory B cells) but also PD-L1 ex vivo and efficiently co-stimulated CD4 T cells of healthy donors (HD), as measured by upregulation of CD25, CD69, inducible co-stimulator (ICOS), and programmed cell death protein 1 (PD-1) and induction of cytokines. While the co-stimulatory capacity of the different CD21(low) B-cell populations was over all comparable to CD21(pos) counterparts of patients and HD, especially switched memory CD21(low) B cells lacked the increased capacity of CD21(pos) switched memory B-cells to induce high expression of ICOS, IL-2, IL-10, and IFN-γ. Acknowledging the limitation of the in vitro setting, CD21(low) B cells do not seem to preferentially support a specific T(h) effector response. In summary, our data implies that CD21(low) B cells of patients with AI diseases can become competent APCs and may, when enriched for autoreactive B-cell receptors (BCR), potentially contribute to AI reactions as cognate interaction partners of autoreactive T cells at sites of inflammation.